Aktienanalyse zu Rockwell Medical Inc (RMTI)RMTIRockwell Medical Inc

Rockwell Medical, Inc. is a healthcare company. The Company develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. The Company operates in the hemodialysis market, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceuticals, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its hemodialysis concentrates products are used to sustain a patient's life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream. The Company is the supplier of liquid and dry, acid and bicarbonate concentrates for dialysis patients in the United States. The Company manufactures hemodialysis concentrates at its facilities in Michigan, South Carolina, and Texas, and the Company manufactures its dry acid concentrate mixers at its facility in Iowa. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Rockwell Medical Inc (RMTI) is a good buy right now due to its current price of $8.17, which is significantly below the analyst price target of $20, indicating a potential upside of over 145%. Additionally, the RSI is at 69.278, suggesting strong momentum, while the stock has shown a 20-day change of +13.63%, indicating positive short-term performance. However, the main risk is the forward P/E ratio of 59.17, which reflects high expectations for future earnings that may not materialize.

3 analysts cover RMTI: 1 rate it Buy, 1 Hold and 1 Sell. The average price target is 3.75.